- Tropic is a UK-based agri-biotech company specializing in gene-edited tropical crops, notably the non-browning banana, and has established itself as a leader in the market with approvals in eleven countries, including the US, Japan, and Brazil.
- In March 2026, Tropic raised $105 million in an oversubscribed Series C funding round to scale the commercial rollout of its banana and rice portfolios, reflecting strong investor confidence in climate-resilient agricultural innovations.
- The company has secured partnerships with major investors such as Forbion Bioeconomy Fund and Corteva, and its products are already in high demand, with the non-browning banana experiencing supply shortages since its commercial launch in 2025.
- Tropic's ideal buyers are procurement teams and food distributors looking for innovative, sustainable crop solutions that address supply chain challenges and consumer demand for longer-lasting produce.
Tropic's workforce is organized into 11 departments, with the largest being Sales at 19 employees, followed by Finance with 13 employees. Community and Social Services and Operations each contribute 9 employees, indicating a balanced distribution across functional areas. The presence of diverse departments, including Engineering and Information Technology, highlights the company's commitment to a multifaceted operational structure.
The company's workforce is distributed across 30 locations, with New York, NY, housing the largest contingent at 15 employees. Other notable locations include Atlanta, GA, San Diego, CA, and Seattle, WA, each contributing 3 employees. The significant headcount categorized as 'Other' suggests a strong remote work culture, allowing for geographic flexibility and a broad talent pool.
